Amylyx Pharmaceuticals, Inc. AMLX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $95.9M+6.1% | $90.4M-1.8% | $92.08M-1.5% | $93.47M+4.3% | $89.6M-13.9% | ||
| $63.37M+0.8% | $62.89M-2.6% | $64.59M-2.5% | $66.25M-8.3% | $72.26M-36.8% | ||
| $159.27M+3.9% | $153.29M-2.2% | $156.68M-20.4% | $196.73M-14.1% | $229.13M-43.0% | ||
| -$159.27M-3.9% | -$153.29M+2.6% | -$157.34M+20.1% | -$196.98M+14.5% | -$230.4M+26.8% | ||
| $9.64M+3.6% | $9.3M+11.7% | $8.33M-13.3% | $9.61M-18.0% | $11.71M-15.2% | ||
| $9.2M+7.0% | $8.6M+15.9% | $7.42M-15.1% | $8.74M-19.9% | $10.91M-13.4% | ||
| —— | -$144.69M+3.5% | -$149.92M+20.4% | -$188.24M+14.2% | -$219.49M+27.4% | ||
| —— | $46K+107% | -$635K0.0% | -$635K0.0% | -$635K-61.6% | ||
| -$150.11M-3.7% | -$144.74M+3.0% | -$149.28M+20.4% | -$187.6M+14.3% | -$218.86M+27.5% | ||
| -$1.48+3.3% | -$1.53+14.5% | -$1.79+28.1% | -$2.49+19.7% | -$3.10+30.0% | ||
| -$1.48+3.3% | -$1.53+14.5% | -$1.79+28.1% | -$2.49+19.7% | -$3.10+30.0% | ||
| 387.6M+6.9% | 362.7M+7.9% | 336.3M+8.1% | 311.1M+7.3% | 290M+6.6% | ||
| 387.6M+6.9% | 362.7M+7.9% | 336.3M+8.1% | 311.1M+7.3% | 290M+6.6% | ||
| —— | —— | —— | —— | —— | ||
| -$159.27M-3.9% | -$153.29M+2.6% | -$157.34M+20.1% | -$196.98M+14.5% | -$230.4M+26.8% | ||
| -$158.8M-3.9% | -$152.77M+2.5% | -$156.76M+20.1% | -$196.3M+14.5% | -$229.66M+26.8% | ||
| -$158.8M-3.9% | -$152.77M+2.5% | -$156.76M+20.1% | -$196.3M+14.5% | -$229.66M+26.8% | ||
| -$159.27M-3.9% | -$153.29M+2.6% | -$157.34M+20.1% | -$196.98M+14.5% | -$230.4M+26.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Amylyx Pharmaceuticals, Inc. profitable?
- Amylyx Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $150.1M over the trailing twelve months, a -45096.2% net margin.
- What are Amylyx Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 100.0% and operating margin is -47349.8%, with a -45096.2% net margin.
- What is Amylyx Pharmaceuticals, Inc.'s earnings per share?
- Amylyx Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-1.48.
- Where does Amylyx Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.